Prescribing information



Watch MS experts present the pivotal data for KESIMPTA®▼ (ofatumumab) in MS, take us through the immunology involved, and discuss real-life patient case studies.

Meeting date: 11 September 2021


KESIMPTA in clinical practice: Redefining the MS treatment landscape in the new normal

Watch MS experts Dr Ben Turner, Dr Matt Craner and Dr David Paling give an overview of the pivotal data for KESIMPTA in the treatment of multiple sclerosis. They will also cover the role of B-cells and immunoglobulins in MS, and provide some case examples to demonstrate the application of KESIMPTA in clinic.

Meeting date: 14 September 2021


Redefining patient care in the new normal with KESIMPTA

Watch MS experts Sarah White, Dr Ben Turner, Noreen Barker and Rachel Morrison present efficacy and safety data from the ASCLEPIOS1 trials of KESIMPTA in multiple sclerosis. They will also discuss their experience in UK practice, not only in terms of outcomes with KESIMPTA, but also of the uptake of self-monitoring of patients through virtual clinics in Scotland.


These meetings were organised and funded by Novartis Pharmaceuticals UK Ltd. The views expressed are those of the speakers and do not necessarily reflect those of Novartis.

MS, multiple sclerosis.

1. Hauser SL, Bar‑Or A, Cohen JA, et al. Ofatumumab versus Teriflunomide in Multiple Sclerosis. New Engl J Med. 2020;383:547‑557.

Rate this content: 
No votes yet
UK | April 2022 | 202661

Ask Speakers


Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]